Skip to main content

Liraglutide (T2DM)


04-23-2020 | GLP-1 agonists | News

Real-world evidence for renoprotective effects of GLP-1 receptor agonists

People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.

03-09-2020 | Liraglutide (T2DM) | News

Liraglutide may reduce CV risk regardless of heart failure

A post-hoc analysis of the LEADER trial suggests that liraglutide reduces cardiovascular risk in people with type 2 diabetes regardless of whether they have heart failure.

09-23-2019 | Children | EASD 2019 | News

RISE compares alpha, beta cells in youth vs adults with early type 2 diabetes

The failure of intensive medication to halt beta-cell decline in children with early type 2 diabetes occurs despite them having better baseline beta-cell and alpha-cell function than newly diagnosed adults, say the RISE researchers.

Read more

Related topics




10-23-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.

In depth

07-03-2019 | Semaglutide | At a glance | Article

A quick guide to the PIONEER trials

medwireNews rounds up the ongoing, reported, and published trials from the PIONEER oral semaglutide program.

10-17-2017 | GLP-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

Journal articles and book chapters

04-05-2018 | Oral combination medications | Review | Article

Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: Symbiotic effects on metabolism and cardiorenal risk

Goncalves E, Bell DSH. Diabetes Ther 2018; 9: 919–926. doi: 10.1007/s13300-018-0420-6

11-02-2017 | Heart failure | Review | Article

Treating disease mechanisms in patients with heart failure and diabetes mellitus

Trang A, Aguilar D. Curr Heart Fail Rep 2017; 14: 445–453. doi: 10.1007/s11897-017-0371-7

10-23-2017 | Insulin | Review | Article

Insulin and its cardiovascular effects: What is the current evidence?

Dongerkery SP, Schroeder PR, Shomali ME. Curr Diab Rep 2017; 17: 120. doi: 10.1007/s11892-017-0955-3

Image Credits